TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03579615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIASP + closed loop device
Description: Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart (standard of care insulin) + closed loop device
Description: Participants will be advised to maintain their usual insulin 24 hours prior to admission.
Study: NCT01354626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary protein
Description: in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided

Intervention type: OTHER
Group type: OTHER
Intervention: low-protein
Description: The control group will get a diet which is according to healthy eating guidelines.
Study: NCT01694212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative Diclofenac eye-drops administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05086003

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined kidney and bone marrow transplantation
Description: Combined kidney and bone marrow transplantation
Study: NCT04251429

Intervention type: OTHER
Group type: OTHER
Intervention: CPH-NEW Healthy Workplace Participatory Program
Description: A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPH-NEW Healthy Workplace Participatory Program
Description: A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
Study: NCT03382600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: 40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study: NCT03734263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
Study: NCT03664063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Treatment with Azithromycin single dose - weight based dosing max 2gm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treatment with Azithromycin single dose - weight based dosing max 2gm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose of Albendazole weight based dosing~- 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single dose of Albendazole weight based dosing~- 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin weight based dosing - max 21mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin weight based dosing - max 21mg
Study: NCT03382600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 Q3W on Day 1 by IV infusion
Study: NCT01035151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Written Cessation Materials
Study: NCT02560740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PerOx Quench
Description: By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
Study: NCT03664063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine weight based dosing - max 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine weight based dosing - max 500mg
Study: NCT03831256

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Traditional integrated prenatal screening
Description: biochemical prenatal screening with or without nuchal translucency by US

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Second-tier Non-invasive prenatal screening (NIPS)
Description: genomics based NIPS after a positive traditional prenatal screen

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First-tier Non-invasive prenatal screening (NIPS)
Description: genomics based NIPS at first trimester

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive prenatal testing for fetal aneuploidy
Description: amniocentesis or chorionic villi sampling (CVS)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive prenatal testing for fetal aneuploidy
Description: amniocentesis or chorionic villi sampling (CVS)
Study: NCT03600363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin (1.0g, bid) as a maintenance therapy in patients with complete remission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebos as a maintenance therapy
Study: NCT03609203

Intervention type: OTHER
Intervention: 10 Weeks of Strength Trailing
Description: Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples

Intervention type: OTHER
Intervention: 10 Weeks of Strength Trailing
Description: Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples

Intervention type: OTHER
Intervention: Group Nutrition Discussion: week 1, week 5 and week 10
Description: Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples

Intervention type: OTHER
Intervention: Group Nutrition Discussion: week 1, week 5 and week 10
Description: Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples
Study: NCT02714465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: hyperbaric oxygen therapy
Study: NCT02957942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1Hz repetitive transcranial magnetic stimulation (rTMS)
Description: 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1Hz repetitive transcranial magnetic stimulation (rTMS)
Description: 1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
Study: NCT04031209

Intervention type: DEVICE
Intervention: G7 Acetabular System
Description: All patients will receive G7 Acetabular System
Study: NCT02249442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (r)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (r)
Study: NCT04106219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered IV.
Study: NCT02560740

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PerOx Quench Placebo
Description: By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
Study: NCT02646111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 weeks without Ribavirin
Description: 12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 weeks with Ribavirin
Description: 12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 weeks with Ribavirin
Description: 12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24 weeks with Ribavirin
Description: 24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
Study: NCT01058863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir® HFA
Description: ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir® HFA
Description: ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
Study: NCT01671670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: In this group, acupuncture is given according to traditional acupuncture theories.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture points will be used in this trial, with needle penetration.
Study: NCT02758795

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NUTRIENT
Description: Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
Study: NCT01691118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihypertensive treatment
Study: NCT00101361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone
Description: Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
Study: NCT04066621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium and Sulbactam Sodium for Injection
Description: daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
Study: NCT00691548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-Zr. 89
Description: Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg).
Study: NCT02403206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Curvilinear Capsulorhexis (CCC)
Description: Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
Study: NCT03554512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth virtual appointment
Description: Appointment with NICU clinician via telehealth equipment.
Study: NCT04075643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D935 Cap. 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D935 Cap. 1 Cap., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-385 Tab. 1 Tab., single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-385 Tab. 1 Tab., single oral administration under fasting condition
Study: NCT01240070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive care
Description: Intensive multi-factorial treat-to-target intervention program designed according to international guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive care
Description: Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
Study: NCT02339714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture combined moxibustion
Description: Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
Study: NCT00533000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Weekly smoking cessation by professional counseling and nicotine substitute on request
Study: NCT01049828

Intervention type: OTHER
Intervention: No intervention
Description: No treatment for tinnitus will occur in this study.
Study: NCT03204825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS
Description: TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
Study: NCT01739595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enclomiphene citrate
Description: oral, capsules, taken one time daily, for 3 months
Study: NCT03500081

Intervention type: DEVICE
Intervention: MRI Scan
Description: The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.

Intervention type: DEVICE
Intervention: MRI Scan
Description: The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
Study: NCT02165007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell graft that are CD34+ selected
Description: The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
Study: NCT03204825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS
Description: TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centred Education
Description: Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centred Education
Description: Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: TENS device use with setting so that the stimulation delivered is ineffective
Study: NCT00065546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen plus choline depletion diet
Description: Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus choline depletion diet
Description: Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-menopausal women with SNPs given a low choline diet
Description: Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
Study: NCT02211157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01731184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
Study: NCT04355611

Intervention type: OTHER
Intervention: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)
Description: Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
Study: NCT02511964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Training at 1% Incline
Description: Six Sessions of Running at 1% incline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Training at 10% Incline
Description: Six Sessions of Running at 10% incline